Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECUSTEC
2016-000997-39Phase 2Unknown
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Shiga-toxin producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) comparing Eculizumab with Placebo (2 arms). Primary endpoint: STEC HUS clinical severity score at day 60. Status: unknown.
02
Drugs
eculizumab
03
Conditions
Shiga-toxin producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS)
Beyond the preview
Go deeper on 2016-000997-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000997-39.